3D Medicines Inc (1244) Fair Value & Analysis

Healthcare · HK · Market cap HK$603M

Below-average quality, and screening another 67% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (HK$0.8300). The favourable scenario is already priced in.
• Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (HK$0.4400 to HK$0.8300) leaves room in how you read the outcome.

Price vs Fair Value (4 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

44‑month range HK$1.67 – HK$124.00 · fair‑value band HK$0.4400 – HK$0.8300 · the HK$2.02 price screens above the HK$0.6600 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

3D Medicines Inc (1244) currently trades at HK$2.02, while our model-based Fair Value estimate is HK$0.6600, implying the stock looks roughly 67.3% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, 3D Medicines Inc generated revenue of HK$356M at a net margin of -49.9%. Revenue declined 38.6% year over year. It earns a return on equity of -29.6%. The balance sheet holds a net cash position of HK$17.5M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.4400 (bear case) to HK$0.8300 (bull case); at HK$2.02, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 80% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -67%, 1244 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People's Republic of China.

Full company description

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People's Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC, and TMB-H advanced cancer; and in Phase II clinical trials G/GEJ, EC, HCC, CRC, NSCLC, microsatellite stable CRC, and dMMR advanced sold tumors. In addition, it provides products which is in development pipeline include 3D189 for multi-indication tumor that has completed Phase I and is in phase III clinical trial for the treatment of acute myeloid leukemia (AML); 3D1001 for the treatment of post-surgical dental pain/cancer pain which is in phase II trial; 3D1002 for cancer pain/osteoarthritis and is in phase II trial; 3D229 (GAS6/AXL) for the treatment of acute myeloid leukemia (AML), kidney cancer, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, and prostate cancer and has completed phase I clinical trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy that is in Phase I clinical trial; 3D011 for advanced malignant solid tumor which is in Phase I clinical trial; 3D1015 for the treatment of metastatic castration-resistant prostate cancer which is in Phase I clinical trial; and 3D057, 3D059, 3D124, and 3D062 for multiple indications tumors which are in Phase I clinical trial. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3D Medicines Inc reported revenue of HK$356M in FY2025 versus HK$60.3M in FY2021, a compound +55.9%/yr. Reported net income was −HK$178M in FY2025.

1244 screens 67% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Peer Group

Biotechnology · 600 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.